Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A; ACCENT Group.

J Clin Oncol. 2007 Oct 10;25(29):4569-74. Epub 2007 Sep 17.

PMID:
17876008
2.

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N.

J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30.

PMID:
17470851
3.

Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N.

J Clin Oncol. 2007 Jun 1;25(16):2205-11. Epub 2007 Apr 30.

PMID:
17470850
4.

Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06.

Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N.

J Clin Oncol. 2007 Feb 1;25(4):424-30. Erratum in: J Clin Oncol. 2007 Dec 1;25(34):5540-1.

PMID:
17264338
5.

Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.

Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ; National Cancer Institute.

J Clin Oncol. 2007 Mar 1;25(7):767-72. Epub 2007 Jan 16.

PMID:
17228023
6.

Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N.

J Clin Oncol. 2006 May 1;24(13):2059-64.

PMID:
16648506
7.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A.

J Clin Oncol. 2005 Dec 1;23(34):8664-70. Epub 2005 Oct 31.

PMID:
16260700
8.

Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program.

Atkins JN, Jacobs SA, Wieand HS, Smith RE, John WJ, Colangelo LH, Vogel VG, Kuebler JP, Cescon TP, Miller BJ, Geyer CE Jr, Wolmark N.

Clin Colorectal Cancer. 2005 Sep;5(3):181-7.

PMID:
16197621
9.

Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.

Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM.

Clin Cancer Res. 2005 Sep 1;11(17):6261-9.

10.

Chemotherapy sensitivity and response assays: are the ASCO guidelines for clinical trial design too restrictive?

Wieand HS.

J Clin Oncol. 2005 May 20;23(15):3643-4; author reply 3646-8. No abstract available.

PMID:
15908687
11.

Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up.

Seixas-Silva JA Jr, Richards T, Khuri FR, Wieand HS, Kim E, Murphy B, Francisco M, Hong WK, Shin DM.

Arch Otolaryngol Head Neck Surg. 2005 Apr;131(4):304-7.

PMID:
15837897
12.

Randomized phase II trials: what does randomization gain?

Wieand HS.

J Clin Oncol. 2005 Mar 20;23(9):1794-5. Epub 2005 Feb 7. No abstract available.

PMID:
15699476
13.
14.

Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.

Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N.

J Natl Cancer Inst. 2004 Aug 4;96(15):1128-32.

PMID:
15292384
15.

A comparison of laparoscopically assisted and open colectomy for colon cancer.

Clinical Outcomes of Surgical Therapy Study Group, Nelson H, Sargent DJ, Wieand HS, Fleshman J, Anvari M, Stryker SJ, Beart RW Jr, Hellinger M, Flanagan R Jr, Peters W, Ota D.

N Engl J Med. 2004 May 13;350(20):2050-9.

16.

Is relative risk reduction a useful measure for patients or families who must choose a method of treatment?

Wieand HS.

J Clin Oncol. 2003 Dec 1;21(23):4263-4. Epub 2003 Oct 27. No abstract available.

PMID:
14581445
18.

Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual.

Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL.

Surg Clin North Am. 2003 Aug;83(4):803-19. Review.

PMID:
12875597
19.

Management of the clinically inapparent adrenal mass ("incidentaloma").

Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS.

Ann Intern Med. 2003 Mar 4;138(5):424-9.

PMID:
12614096
20.

Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials.

Dignam JJ, Ye Y, Colangelo L, Smith R, Mamounas EP, Wieand HS, Wolmark N.

J Clin Oncol. 2003 Feb 1;21(3):413-20.

PMID:
12560428
21.

Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.

Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS.

J Clin Oncol. 2003 Jan 15;21(2):241-50.

PMID:
12525515
22.

Revision of the American Joint Committee on Cancer staging system for breast cancer.

Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL.

J Clin Oncol. 2002 Sep 1;20(17):3628-36.

PMID:
12202663
23.

UFT/leucovorin vs 5-FU/leucovorin in colon cancer.

Smith RE, Lembersky BC, Wieand HS, Colangelo L, Mamounas EP.

Oncology (Williston Park). 2000 Oct;14(10 Suppl 9):24-7.

24.

Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, Wexler M, Prager D, Cruz AB Jr, Gordon PH, Petrelli NJ, Deutsch M, Mamounas E, Wickerham DL, Fisher ER, Rockette H, Fisher B.

J Natl Cancer Inst. 2000 Mar 1;92(5):388-96.

PMID:
10699069
25.

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS.

J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8.

PMID:
10491430
26.

UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer.

Smith R, Wickerham DL, Wieand HS, Colangelo L, Mamounas EP.

Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):44-7.

27.
28.

Future directions in the adjuvant treatment of colon cancer.

Mamounas EP, Wieand HS, Jones J, Wickerham DL, Wolmark N.

Oncology (Williston Park). 1997 Sep;11(9 Suppl 10):44-7.

29.

Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.

O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A.

J Clin Oncol. 1998 Jan;16(1):295-300.

PMID:
9440756
30.

Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.

Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, Levitt R, Suman VJ, Witzig TE, Wieand HS, Miller LL, Moertel CG.

N Engl J Med. 1997 Jun 19;336(25):1776-80.

31.

A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03.

Hyams DM, Mamounas EP, Petrelli N, Rockette H, Jones J, Wieand HS, Deutsch M, Wickerham L, Fisher B, Wolmark N.

Dis Colon Rectum. 1997 Feb;40(2):131-9.

PMID:
9075745
32.

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.

O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS.

J Clin Oncol. 1997 Jan;15(1):246-50.

PMID:
8996149
33.

Flow-cytometric analysis of deoxyribonucleic acid content in advanced ovarian carcinoma: its importance in long-term survival.

Zanetta G, Keeney GL, Cha SS, Farr GH Jr, Katzmann JA, Wieand HS, Edmonson JH, Podratz KC.

Am J Obstet Gynecol. 1996 Nov;175(5):1217-25.

PMID:
8942491
35.

A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer.

Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE.

J Natl Cancer Inst. 1996 Aug 7;88(15):1039-45.

PMID:
8683634
36.

DNA index by flow cytometric analysis: an additional prognostic factor in advanced ovarian carcinoma without residual disease after primary operation.

Zanetta G, Keeney GL, Cha SS, Wieand HS, Katzmann JA, Podratz KC.

Gynecol Oncol. 1996 Aug;62(2):208-12.

PMID:
8751551
37.
38.

Wound recurrence following conventional treatment of colorectal cancer. A rare but perhaps underestimated problem.

Reilly WT, Nelson H, Schroeder G, Wieand HS, Bolton J, O'Connell MJ.

Dis Colon Rectum. 1996 Feb;39(2):200-7.

PMID:
8620788
39.

Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.

Ingle JN, Krook JE, Mailliard JA, Hartmann LC, Wieand HS.

Am J Clin Oncol. 1995 Dec;18(6):498-501.

PMID:
8526193
40.
41.

Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer.

Wiesenfeld M, O'Connell MJ, Wieand HS, Gonchoroff NJ, Donohue JH, Fitzgibbons RJ Jr, Krook JE, Mailliard JA, Gerstner JB, Pazdur R.

J Clin Oncol. 1995 Sep;13(9):2324-9.

PMID:
7666090
42.

Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study.

Donohue JH, Williams S, Cha S, Windschitl HE, Witzig TE, Nelson H, Fitzgibbons RJ Jr, Wieand HS, Moertel CG.

J Clin Oncol. 1995 Jul;13(7):1671-8.

PMID:
7602357
43.

c-erbB-2 and p53 expression in fallopian tube carcinoma.

Lacy MQ, Hartmann LC, Keeney GL, Cha SC, Wieand HS, Podratz KC, Roche PC.

Cancer. 1995 Jun 15;75(12):2891-6.

PMID:
7773939
44.

Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina.

Long HJ 3rd, Cross WG, Wieand HS, Webb MJ, Mailliard JA, Kugler JW, Tschetter LK, Kardinal CG, Ebbert LP, Rayson S.

Gynecol Oncol. 1995 May;57(2):235-9.

PMID:
7729741
45.

Proposed phase III trial comparing laparoscopic-assisted colectomy versus open colectomy for colon cancer.

Nelson H, Weeks JC, Wieand HS.

J Natl Cancer Inst Monogr. 1995;(19):51-6.

PMID:
7577206
46.

p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis.

Cunningham JM, Ingle JN, Jung SH, Cha SS, Wold LE, Farr G, Witzig TE, Krook JE, Wieand HS, Kovach JS.

J Natl Cancer Inst. 1994 Dec 21;86(24):1871-3. No abstract available.

PMID:
7990162
47.

Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.

O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA.

N Engl J Med. 1994 Aug 25;331(8):502-7.

48.

Advanced colorectal adenocarcinoma: treatment with amonafide.

Marschke RF Jr, Wieand HS, O'Connell MJ, Rubin J, Schutt AJ, Burch PA, Kovach JS.

J Natl Cancer Inst. 1994 Jun 15;86(12):944-5. No abstract available.

PMID:
8196086
49.

Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group.

Loprinzi CL, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW, Bartel J, Law M, Bateman M, Klatt NE, et al.

J Clin Oncol. 1994 Mar;12(3):601-7.

PMID:
8120560
50.

Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.

Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK.

J Clin Oncol. 1994 Feb;12(2):412-6.

PMID:
8113849

Supplemental Content

Loading ...
Support Center